Drugs / Moroctocog alfa(AF-CC)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02492984 | Apr 2015 → Jul 2016 | hemophilia A | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00765726 | Feb 2009 → Jul 2011 | hemophilia A | Pfizer | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Moroctocog alfa(AF-CC) | “This study aimed to evaluate the efficacy, safety, and recovery data of moroctocog alfa (AF-CC) in patients with hemophilia participating in two open-label studies, both...” PMID 33269010 ↗ Nov 2020 |
| Known as | Xyntha (Moroctocog-alfa (AF-CC) | “Xyntha (Moroctocog-alfa (AF-CC)” NCT02492984 ↗ |
| Modality | Protein / enzyme biologic | “Xyntha (Moroctocog-alfa (AF-CC), Recombinant FVIII)” NCT02492984 ↗ |
| Route | Intravenous | “Enrolled subjects will be treated with intravenous infusions of Xyntha” NCT02492984 ↗ |